What was the overall valuation of the US opioids market in 2024?

The overall market valuation was $13.2 Billion in 2024. Read More

What is the projected market valuation for the US opioids market by 2035?

The projected valuation for 2035 is $17.2 Billion. Read More

What is the expected CAGR for the US opioids market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 2.44%. Read More

Which companies are considered key players in the US opioids market?

Key players include Purdue Pharma, Johnson & Johnson, Teva Pharmaceutical Industries, Mylan N.V., Endo International, Mallinckrodt Pharmaceuticals, Amgen Inc., and Boehringer Ingelheim. Read More

What are the segment valuations for Natural Opioids in 2025?

The segment valuation for Natural Opioids is projected to be between $4.5 Billion and $5.5 Billion in 2025. Read More

How does the valuation of Semi-synthetic Opioids change from 2024 to 2025?

The valuation for Semi-synthetic Opioids is expected to increase from $4.0 Billion in 2024 to $5.0 Billion in 2025. Read More

What is the projected valuation for Pain Management applications in 2025?

The projected valuation for Pain Management applications is between $8.0 Billion and $10.0 Billion in 2025. Read More

What is the expected market size for Chronic Pain Patients in 2025?

The expected market size for Chronic Pain Patients is projected to be between $5.0 Billion and $6.5 Billion in 2025. Read More

What are the projected valuations for the different routes of administration in 2025?

In 2025, Oral is projected at $6.5 Billion, Injectable at $3.8 Billion, Transdermal at $2.5 Billion, Rectal at $1.2 Billion, and Nasal at $3.2 Billion. Read More

What is the expected growth trend for the US opioids market in the coming years?

The market appears to be on a growth trend, with a projected increase in valuation from $13.2 Billion in 2024 to $17.2 Billion by 2035. Read More

US Opioids Market

ID: MRFR/HC/13077-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US Opioids Market Research Report: Size, Share, Trend Analysis By Types (Natural Opioids, Semi-Synthetic Opioids, Fully Synthetic Opioids), By Applications (Pain Management, Anesthesia, Cough Suppression, Diarrhea Treatment), By Route of Administration (Oral, Injectable, Transdermal, Topical) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Natural Opioids
  2. 4.1.2 Semi-synthetic Opioids
  3. 4.1.3 Fully Synthetic Opioids
  4. 4.1.4 Opioid Derivatives
2. 4.2 Healthcare, BY Route of Administration (USD Billion)
  1. 4.2.1 Oral
  2. 4.2.2 Injectable
  3. 4.2.3 Transdermal
  4. 4.2.4 Rectal
  5. 4.2.5 Nasal
3. 4.3 Healthcare, BY Therapeutic Application (USD Billion)
  1. 4.3.1 Pain Management
  2. 4.3.2 Cough Suppression
  3. 4.3.3 Diarrhea Treatment
  4. 4.3.4 Anesthesia
4. 4.4 Healthcare, BY Patient Population (USD Billion)
  1. 4.4.1 Chronic Pain Patients
  2. 4.4.2 Postoperative Pain Patients
  3. 4.4.3 Cancer Patients
  4. 4.4.4 Palliative Care Patients
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Purdue Pharma (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Johnson & Johnson (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Teva Pharmaceutical Industries (IL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Mylan N.V. (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Endo International (IE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Mallinckrodt Pharmaceuticals (IE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen Inc. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Boehringer Ingelheim (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY THERAPEUTIC APPLICATION
5. 6.5 US MARKET ANALYSIS BY PATIENT POPULATION
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY TYPE, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
16. 6.16 HEALTHCARE, BY THERAPEUTIC APPLICATION, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY THERAPEUTIC APPLICATION, 2024 TO 2035 (USD Billion)
18. 6.18 HEALTHCARE, BY PATIENT POPULATION, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY PATIENT POPULATION, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY PATIENT POPULATION, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Natural Opioids
Semi-synthetic Opioids
Fully Synthetic Opioids
Opioid Derivatives

Healthcare By Route of Administration (USD Billion, 2025-2035)

Oral
Injectable
Transdermal
Rectal
Nasal

Healthcare By Therapeutic Application (USD Billion, 2025-2035)

Pain Management
Cough Suppression
Diarrhea Treatment
Anesthesia

Healthcare By Patient Population (USD Billion, 2025-2035)

Chronic Pain Patients
Postoperative Pain Patients
Cancer Patients
Palliative Care Patients

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”